Contains Nonbinding Recommendations

Draft Guidance on Dronabinol

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Dronabinol

Form/Route: Capsule/Oral

Recommended study: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 5 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: Due to safety concerns, the bioequivalence study should be conducted using the 5 mg strength. Because of the risk of syncopal events related to orthostatic hypotension, precautions to prevent syncopal events and injury due to syncopal events are recommended during the conduct of the bioequivalence study. Subjects should be encouraged to remain supine or in a reclining position during the first three (3) hours after dosing. If it is necessary for a subject to rise during the first three (3) hours after dosing, they should only do so with assistance. Subjects should also be assisted when rising for the first time after dosing.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in vivo
   Strength: 5 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional comments: Please see comments above. Refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Dronabinol, and its active metabolite, 11-hydroxy-delta-9-THC, in plasma

Bioequivalence based on (90% CI): Dronabinol

Waiver request of in vivo testing: 2.5 mg and 10 mg based on (i) acceptable bioequivalence studies on the 5 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii)
proportional similarity of the formulations across all strengths. Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in vivo testing.

**Dissolution test method and sampling times:**

**Please note that a Dissolution Methods Database** is available to the public at the OGD website at [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.